Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial

被引：8

作者：

Conte, Benedetta ^{[1
,2
]}

Bruzzone, Marco ^{[3
]}

Lambertini, Matteo ^{[4
,5
]}

Poggio, Francesca ^{[1
]}

Bighin, Claudia ^{[1
]}

Blondeaux, Eva ^{[1
]}

De Laurentiis, Michelino ^{[6
]}

Valle, Enrichetta ^{[7
]}

Cognetti, Francesco ^{[8
]}

Nistico, Cecilia ^{[9
]}

De Placido, Sabino ^{[10
]}

Garrone, Ornella ^{[11
]}

Gamucci, Teresa ^{[12
,13
]}

Montemurro, Filippo ^{[14
]}

Puglisi, Fabio ^{[15
,16
]}

Cardinali, Barbara ^{[17
]}

Fregatti, Piero ^{[18
,19
]}

Miglietta, Loredana ^{[1
]}

Boccardo, Francesco ^{[4
]}

Ceppi, Marcello ^{[3
]}

Del Mastro, Lucia ^{[17
]}

机构：

[1] IRCCS Osped Policlin San Martino, Med Oncol Unit 2, Largo Rosanna Benzi 10, I-16132 Genoa, GE, Italy

[2] August Pi & Sunyer Biomed Res Inst, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149, Barcelona 08036, Spain

[3] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Largo Rosanna Benzi 10, I-16132 Genoa, GE, Italy

[4] IRCCS Osped Policlin San Martino, UOC Clin Oncol Med, Dept Med Oncol, Largo Rosanna Benzi 10, I-1632 Genoa, GE, Italy

[5] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Viale Benedetto XV 10, I-16132 Genoa, GE, Italy

[6] Ist Nazl Tumori Fdn G Pascale, Breast Unit, Via Mariano Semmola 53, I-80131 Naples, NA, Italy

[7] Osped Businco, Dept Med Oncol, Via Edward Jenner 1, I-09121 Cagliari, CA, Italy

[8] Univ Roma La Sapienza, Dept Clin & Mol Med, Viale Regina Elena 324, I-00161 Rome, RM, Italy

[9] Ist Nazl Tumori Regina Elena, Dept Med Oncol 1, Via Elio Chianesi 53, I-00128 Rome, RM, Italy

[10] Univ Naples Federico II, Dept Clin Med & Surg, Via Sergio Pansini 5, I-80131 Naples, NA, Italy

[11] Azienda Osped Santa Croce & Carle, Dept Oncol, Breast Unit, Via Michele Coppino 26, I-12100 Cuneo, CN, Italy

[12] Osped Sandro Pertini, Dept Med Oncol, Via Monti Tiburtini 385-389, I-00157 Rome, RM, Italy

[13] Osped SS Trinita, Dept Med Oncol, I-03039 Sora, FR, Italy

[14] FPO IRCCS, Candiolo Canc Inst, Multidisciplinary Oncol Outpatient Clin, Str Prov 42, I-10060 Turin, TO, Italy

[15] Univ Udine, Dept Med, Piazzale Massimiliano Kolbe 4, I-33100 Udine, Italy

[16] Natl Canc Inst, Dept Med Oncol, IRCCS Ctr Riferimento Oncol Aviano, Via Franco Gallini 2, I-33081 Aviano, PN, Italy

[17] IRCCS Osped Policlin San Martino, Breast Unit, Largo Rosanna Benzi 10, I-16132 Genoa, GE, Italy

[18] Univ Genoa, Dept Surg Sci & Integrated Diagnost DISC, Viale Benedetto XV 6, I-1612 Genoa, GE, Italy

[19] IRCCS Policlin San Martino, Dept Surg, Largo Rosanna Benzi 10, I-1632 Genoa, GE, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 136卷

关键词：

Breast cancer; Dose-dense chemotherapy; Hormone receptor-positive; Luminal subtype; INTERNATIONAL EXPERT CONSENSUS; PHASE-III; PLUS CYCLOPHOSPHAMIDE; PRIMARY THERAPY; WOMEN; DOCETAXEL; SURVIVAL; BENEFIT; KI67; RECURRENCE;

D O I：

10.1016/j.ejca.2020.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Methods: Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) >= 20%; luminal B-like cohort as having a Ki67 >= 20% and/or a PgR < 20%. Results: Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4-84.5) and 70.5% (66.5-74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2-94.1) and 85.1% (81.7-87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54-0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40-0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59-1.33]; unadjusted HR for OS 0.83 [95% CI 0.45-1.54]). Conclusions: No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：43 / 51

页数：9

共 50 条

[21] Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER-2-negative breast cancer
Ma, Sung Jun
Oladeru, Oluwadamilola T.
Singh, Anurag K.
BREAST JOURNAL, 2020, 26 (10) : 2026 - 2030
[22] New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Brett, Jamie O.
Mayer, Erica L.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (06) : 594 - 610
[23] Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy
Honma, Naoko
Horii, Rie
Iwase, Takuji
Saji, Shigehira
Younes, Mamoun
Ito, Yoshinori
Akiyama, Futoshi
BREAST CANCER, 2015, 22 (01) : 71 - 78
[24] Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review
de Mello Morais Mata, Danilo Giffoni
Carmona, Carlos Amir
Eisen, Andrea
Trudeau, Maureen
CURRENT ONCOLOGY, 2022, 29 (07) : 4956 - 4969
[25] Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
Papakonstantinou, Antroula
Matikas, Alexios
Bengtsson, Nils Olof
Malmstrom, Per
Hedayati, Elham
Steger, Guenther
Untch, Michael
Hubbert, Laila
Johansson, Hemming
Hellstrom, Mats
Gnant, Michael
Loibl, Sibylle
Greil, Richard
Moebus, Volker
Foukakis, Theodoros
Bergh, Jonas
CANCER, 2020, 126 (06) : 1175 - 1182
[26] Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey
Fekih, Mahmoud
Petit, Thierry
Zarca, Daniel
Guinebretiere, Jean-Marc
Andre, Fabrice
Pierga, Jean-Yves
Namer, Moise
Gligorov, Joseph
Delaloge, Suzette
BULLETIN DU CANCER, 2014, 101 (10) : 918 - 924
[27] Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study
Wang, Xinguang
Fan, Zhaoqing
Wang, Xing
He, Yingjian
Liu, Yiqiang
Wang, Xiang
Zhang, Bailin
Jiang, Zefei
Wang, Tao
Yu, Zhigang
Wang, Fei
Liu, Yinhua
Li, Yanping
Zhang, Jianguo
Luo, Bin
Jiang, Hongchuan
Wang, Tianfeng
Xie, Yuntao
Li, Jinfeng
Ouyang, Tao
BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (03) : 301 - 310
[28] Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates
Gonzalez-Hurtado, Daniel
Rivero, Sergio
Perez-Vargas, Juan Carlos Samame
Petracci, Fernando E.
BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
[29] Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare
Mueller, Volkmar
Fasching, Peter A.
Nabieva, Naiba
Fehm, Tanja N.
Thill, Marc
Schmidt, Marcus
Kuehn, Thorsten
Banys-Paluchowski, Maggie
Belleville, Erik
Juhasz-Boess, Ingolf
Untch, Michael
Kolberg, Hans-Christian
Harbeck, Nadia
Aktas, Bahriye
Stickeler, Elmar
Kreuzeder, Julia
Hartkopf, Andreas D.
Janni, Wolfgang
Ditsch, Nina
GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : 673 - 685
[30] CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
Agostinetto, E.
Vian, L.
Caparica, R.
Bruzzone, M.
Ceppi, M.
Lambertini, M.
Ponde, N.
de Azambuja, E.
ESMO OPEN, 2021, 6 (02)

← 1 2 3 4 5 →